Screener
CRISPR Therapeutics CRSP Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
FAQ
- What is CRISPR Therapeutics's free cash flow?
- CRISPR Therapeutics (CRSP) reported free cash flow of -$109.4M in Q1 2026.
- How has CRISPR Therapeutics's free cash flow changed year-over-year?
- CRISPR Therapeutics's free cash flow decreased by 102.0% year-over-year, from -$54.15M to -$109.4M.
- What is the long-term trend for CRISPR Therapeutics's free cash flow?
- Over 3 years (2022 to 2025), CRISPR Therapeutics's free cash flow has grown at a -13.4% compound annual growth rate (CAGR), from -$532.93M to -$345.93M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about CRISPR Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude